KIMBERLY-CLARK* KIMVENT* BAL Cath Bronchial Aspirate ...

Kimberly-Clark *
KimVent *
Bronchial Aspirate Sampling Catheter
A microbiologically confirmed diagnosis of lower lung
disease is essential to effective antibiotic management. 5
– Ventilator-associated pneumonia (VAP) affects up to 28% of ventilated
patients 1 , with a mortality rate of up to 33% 2
– There's much debate concerning methods of diagnosis of VAP. Use of
clinical criteria alone is considered problematic. 3
– Culturing endotracheal aspirates as a method of diagnosis has been
shown to yield false positives of 18% and false negatives of 18% 4,
– Without a microbiologically-based diagnosis, inappropriate
or inadequate antibiotic therapy may be prescribed, which can result
in the emergence of multiple-drug resistance and increased mortality 6
Providing the right data for accurate diagnoses
and more effective, targeted treatment
Kimberly-Clark* KimVent* BAL Cath* Bronchial Aspirate Sampling
Catheter safely samples a patient's lower respiratory tract secretions,
giving physicians the data they need to make an accurate lung infection
diagnosis and prescribe targeted antibiotic treatment 5 . And targeted
treatment is critical to reducing antibiotic costs.6
“An accurate microbiological diagnosis of VAP is
likely to be the key element in ensuring appropriate
antibiotic coverage [and] limiting the use and duration
of empirically prescribed broad-spectrum antibiotics.” 7
–– Intensive Care Mediane, 2004. Yu, VL nd Singh, N,

KimVent * VAP S
KimVent *
BAL Cath * Bronchial Aspirate Sampling Catheter
Proven to reduce false microbial findings by 23.8% 4
With a soft, cushioned directional tip, KimVent* BAL Cath* Catheter enables safe and quick
retrieval of lower respiratory tract samples, which have been shown to reduce false positives
or false negatives by 23.8% compared to cultures of endotracheal aspirate samples. 4 These
secretions from the distal airway can help identify infectious pathogens of the lung.
KimVent* BAL Cath* catheters have a demonstrated history
of safe use. More than 200,000 have been used in practice
since 2001 with no reported adverse events. 9
Directional tip allows
right or left lung sampling
3
3
Studies have shown
nonbronchoscopic BAL
to be as effective a diagnostic
tool as bronchoscopic BAL 3 or
protected brush specimen (PSB)
Can be performed bedside in minutes
by trained respiratory therapist
or other clinician
Soft, cushioned, radiopaque
directional tip
is safer for patients when
sampling is from the lower lung

Equips physicians with the power to target antibiotic treatment ––
and reduce antibiotic use.
Enables physicians to significantly reduce unnecessary antibiotics, discontinuing initial drug therapy in as many
as 15-30% of suspected cases. The use of bronchoalveolar lavage as a tool to help diagnose lower lung disease
has been shown to reduce significantly both antibiotic usage 3 and cost. 8
Can help physicians target or de-escalate antibiotic therapy
in an estimated 39%-48% of patients receiving initial
broad-spectrum therapy. 6
Convenient Kimvent* BAL Cath* Prep Pack
includes all accessories needed to quickly perform
nonbronchoscopic BAL at the bedside
Also available:
NEW Kimberly-Clark* Kimvent*
Multi-Access Port Closed Suction System
NEW
Provides easy access for BAL while maintaining a
closed circuit to reduce risk of cross-contamination.
olutions –
Helping You Protect Your Patients From VAP

As a global leader in VAP prevention,
Kimberly-Clark* offers a comprehensive
range of products, education, in-services
training, and compliance programs to assist
you as you develop your best-practice protocol
that can help protect your patients from VAP.
n Approximately 86% of hospital-associated
pneumonia is linked with mechanical
ventilation
n Each incidence of VAP prolongs a patient's
ICU stay by 4-6 days and generates
an increased cost of $20,000 to $40,000
FPO
n VAP may account for up to 60%
of all deaths due to HAIs
Kimberly-Clark* Kimvent* Solutions:
Closed Suction Systems
Endotracheal Tubes
Diagnostic Catheters
Oral Care Solutions
FPO
Kimberly-Clark *
KimVent *
VAP Solutions
Kimberly-Clark* KimVent* BAL Cath*
Bronchial Aspirate Sampling Catheter
Stock # Outer Catheter Inner Catheter Packaging
FPO
For more information, please call your sales
representative, or visit our website at:
www.kcheathcare.com/VAP
142 16F 12Fr 5/Case
The Kimberly-Clark Advantage*
Clinical Education
Ongoing Customer Support
Expert Sales Force
Tools & Best Practices
Clinical Research
Commitment to Excellence
Infection prevention website:
www.HAIwatch.com
1 Chastre J, Fagon J. Ventilator Associated Pneumonia, Crit Care Med, 2002: 165:867-903.
2 CDC, Guidelines for Preventing Healthcare-Associated Pneumonia, 2003. Recommendations of CDC and Healthcare Infection Control
Practices Committee, MMWR, 2004; 53 (No. RR-3).
3 Morris AC, Kallirroi K, Simpson AJ, Wilkinson TS, Everingham KE, Kerslake D, Laurenson, IF, Raby S, Swann DF, Walsh TS. Evaluation of
diagnostic methodology on the reported incidence of ventilator-associated pneumonia. Thorax, Feb 12 2009.
4 Fujitani, S, Cohen-Melamed MH, Tuttle RP, Delgado E, Yasuhiko T, Darby, JM. Comparison of semi-quantitative endotracheal aspirates
to quantitative non-bronchoscopic bronchoalveolar lavage in diagnosing ventilator-associated pneumonia. Respiratory Care,
November 2009 V. 54, No 11, 1453-1461.
5 American Thoracic Society Guidelines for the Management of Adults with Hospital-acquired, Ventilator-associated,
and Healthcare-associated Pneumonia. American Journal of Respiratory and Critical Care Medicine, V. 171, 388-416 (2005).
6 Kollef MH, Ward S. The influence of mini-BAL cultures on patient outcomes: implications for the antibiotic management of ventilatorassociated
pneumonia. Chest 1998: 113(2); 412-420.
7 Yu VL, Singh N, Excessive antimicrobial usage causes measurable harm to patients with suspected ventilator-associated pneumonia.
Intensive Care Med 2004:30(5): 735-738.
8 Ost, DE, et al. Decision analysis of antibiotic and diagnostic strategies in VAP. Am J Respir Care Med, 2003; 168(9): 1060-7.
9 Kimberly-Clark PIR data on file, product code 141. We have manufactured 200,000 units between 1994 and 2009 without any reported
patient injury.
*Registered Trademark or Trademark of Kimberly-Clark Worldwide, Inc.
©2010 KCWW. All rights reserved. Hxxxxxxx